The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1677-1685

  Watanabe, Sanae ^a   Okura, Takafumi ^a   Kurata, Mie ^a   Irita, Jun ^a   Manabe, Seiko ^a   Miyoshi, Ken ichi ^a   Fukuoka, Tomikazu ^a   Murakami, Kazuo ^b   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MATSUYAMA RED CROSS HOSPITAL   (Japan)

Author keywords

adiponectin; hypertension; insulin resistance; losartan; microalbuminuria

Indexed keywords

ADIPONECTIN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOSARTAN; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; JAPAN; MALE; MICROALBUMINURIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 33845233426     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.012     Document Type: Article

References (36)

1. Haffner S.M. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 84 (1999) 11J-14J
2. Tsuchihashi K., Hikita N., Hase M., et al. Role of hyperinsulinemia in atherosclerotic coronary arterial disease: Studies of semi-quantitative coronary angiography. Intern Med 38 (1999) 691-697
3. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
4. DeFronzo R.A., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
5. Rantala A.O., Kauma H., Lilja M., et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 245 (1999) 163-174
6. Iimura O. Insulin resistance and hypertension in Japanese. Hypertens Res 19 Suppl 1 (1996) S1-S8
7. Lind L., Berne C., and Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 13 (1995) 1457-1462
8. Watanabe S., Okura T., Kitami Y., and Hiwata K. Carotid hemodynamic alteration in hypertensive patients with insulin resistance. Am J Hypertens 15 (2002) 851-856
9. Scherer P.E., Williams S., Fogliano M., et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
10. Okamoto Y., Arita Y., Nishida M., et al. An adipocytederived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32 (2000) 47-50
11. Ouchi N., Kihara S., Arita Y., et al. Novel modulator of endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
12. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocytederived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1299-1301
13. Higashiura K., Ura N., Ohata J., et al. Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol (Oxf) 61 (2004) 753-759
14. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosder Thromb Vasc Biol 20 (2000) 1595-1599
15. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86 (2001) 1930-1935
16. Kumada M., Kihara S., Sumitsuji S., et al., CAD Study Group. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
17. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 (2003) 671-674
18. Pilz S., Maerz W., Weihrauch G., et al., Ludwigshafen Risk and Cardiovascular Health (LURIC) Group. Adiponectin serum concentrations in men with coronary artery disease: The LUdwigshafen Rlsk and Cardiovascular Health (LURIC) study. Clin Chim Acta 364 (2006) 251-255
19. Kern P.A., Saghizadeh M., Ong J.M., et al. The expression of tumor necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95 (1995) 2111-2119
20. Hotamisligil G.S. Inflammation, THF alpha, and insulin resistance. In: LeRoith D., Taylor S.I., and Olefsky J.M. (Eds). Diabetes Mellitus: A Fundamental and Clinical Text (2004), Lippincott, New York, NY 953-962
21. Fliser D., Buchholz K., Haller H., and European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators . Andinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
22. Manabe S., Okura T., Watanabe S., et al. Effects of angiotensin II receptor blockade with valsartan on pro-in flammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 46 (2005) 735-739
23. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
24. Dahlof B., Devereux R.B., Kjeldsen S.E., et al., LIFE Study Group. Cardiovascular morbidity and mor tality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE: A randomised trial against atenolol. Lancet 359 (2002) 995-1003
25. Julius S., Kjeldsen S.E., Weber M., et al., VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine. The VALUE randomised trial. Lancet 363 (2004) 2022-2031
26. Brenner B.M., Cooper M.E., de Zeeuw D., et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
27. Furuhashi M., Ura N., Higashiura K., et al. Blockade of the renin-angiotensin system increases adiponectin con centrations in patients with essential hypertension. Hypertension 42 (2003) 76-81
28. Matsuzawa Y. Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Nature Clin Pract Cardiovasc Med 3 (2006) 35-42
29. Maeda K., Okubo K., Shimomura I., et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abun dant gene transcript 1). Biochefn Biophys Res Commun 221 (1996) 286-289
30. Murakami H., Ura N., Furuhashi M., et al. Role of adiponectin in insulinresistant hypertension and atherosclerosis. Hypertens Res 26 (2003) 705-710
31. Wallace T.M., and Matthews D.R. The assessment of insulin resistance in man. Diabet Med. 19 (2002) 527-534
32. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
33. Bonora E., Targher G., Alberiche M., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 (2000) 57-63
34. Clasen R., Schupp M., Foryst-Ludwig A., et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46 (2005) 137-143
35. Schupp M., Lee L.D., Frost N., et al. Regulation of peroxisome proliferatoractivated receptor gamma activity by losartan metabolites. Hypertension 47 (2006) 586-589
36. Sharma A.M., Janke J., Gorzelniak K., et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40 (2002) 609-611